The Endocannabinoid System: Novel Pathway for Cardiometabolic Risk‐Factor Reduction
@article{Woods2007TheES, title={The Endocannabinoid System: Novel Pathway for Cardiometabolic Risk‐Factor Reduction}, author={S. Woods}, journal={Journal of the American Academy of Physician Assistants}, year={2007}, volume={20}, pages={7–10} }
Although rimonabant has been approved for use in several countries, the Food and Drug Administration has expressed concern about the potential for adverse neurologic and psychiatric effects, considering the widespread distribution of CB1 receptors in the brain. While more research is clearly needed, the clinical evidence shows that CB1-receptor blockade with rimonabant improves multiple cardiovascular and metabolic variables, including body weight and waist circumference, HDL-C, triglycerides… CONTINUE READING
Topics from this paper
4 Citations
Pharmacological tools in endocannabinoid neurobiology.
- Chemistry, Medicine
- Current topics in behavioral neurosciences
- 2009
- 4
Targeting Intermediary Metabolism in the Hypothalamus as a Mechanism to Regulate Appetite
- Biology, Medicine
- Pharmacological Reviews
- 2010
- 62
- PDF
References
SHOWING 1-10 OF 16 REFERENCES
Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors.
- Medicine
- The American journal of medicine
- 2007
- 19
- PDF
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
- Medicine
- The New England journal of medicine
- 2005
- 1,322
- PDF
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
- Medicine
- The Lancet
- 2005
- 1,237
- Highly Influential
- PDF
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
- Medicine
- JAMA
- 2006
- 1,172
- PDF
The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.
- Biology, Medicine
- The Journal of clinical investigation
- 2003
- 1,095
- PDF
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.
- Biology, Medicine
- The Journal of clinical investigation
- 2005
- 965
- PDF
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.
- Medicine, Biology
- Molecular pharmacology
- 2003
- 616
- PDF
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
- Medicine
- The Lancet
- 2006
- 702
- Highly Influential
- PDF
Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide
- Medicine, Chemistry
- British Journal of Nutrition
- 2004
- 130
- PDF
Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice
- Chemistry, Medicine
- International Journal of Obesity
- 2005
- 310
- PDF